LG Chem Holds 20th LGS Symposium…Announcement of Interim Analysis of Utropin Safety and Effectiveness for Children with Hypothesis
Jun 10, 2025
|
LG Chem, which launched Utropin, the first treatment for hypodenosis in Korea, in 1993 to replace imported products, has since diversified its product formulation into liquid and pen methods.
Since 2012, it has been conducting 'LGS' to secure long-term growth hormone administration data for Korean children for the first time in Korea. This study is a long-term project to recruit 10,000 children with hypotension by 2027 and follow up on the safety and effectiveness of utropins until 2035. As of the end of last year, the 12th year of the study, the number of registered students was about 7,000.
At this symposium, Professor Hong Yong-hee of Soon Chun Hyang University Bucheon Hospital presented the results of the safety and validity of the 12th year of Utropin and said that Utropin effectively improved the height growth of children with low height. There was a tendency to approach the peer standard height according to the course of treatment, and in the case of children with growth hormone deficiency and unfair lightweight, the standard deviation before starting treatment was -2.5 to -0.9 after 48 months of treatment, gradually approaching the peer standard. In idiopathic hypotension, the treatment effect was -2.5 to -1.1. The standard deviation can be analyzed to be closer to the mean as it approaches zero.
Lee Hae-sang, a professor at Ajou University Hospital, then announced the effectiveness and safety of Utropin as a long-term treatment method by analyzing only children registered with unfair lightweight children in LGS in detail.
Son Ji-woong, head of LG Chem's Life Science Business Division, said, `LGS will be the first and largest growth hormone treatment database in Korea that can be applied to children with hypodermia in Korea.'
This article was translated by Naver AI translator.
